Prostate cancer imaging

被引：77

作者：

Fuchsjager, M.

Shukla-Dave, A.

Akin, O.

Barentsz, J.

Hricak, H. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY USA

[3] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands

来源：

ACTA RADIOLOGICA | 2008年 / 49卷 / 01期

关键词：

CT; MR diffusion/perfusion; MR imaging; MR spectroscopy; neoplasms; primary; prostate;

D O I：

10.1080/02841850701545821

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

As prostate cancer is a biologically heterogeneous disease for which a variety of treatment options are available, the major objective of prostate cancer imaging is to achieve more precise disease characterization. Magnetic resonance imaging (MRI) may enhance the staging of prostate cancer compared with clinical evaluation, transrectal ultrasound, or computed tomography (CT), and allows concurrent evaluation of prostatic, periprostatic, and pelvic anatomy. In clinical practice, the fusion of MRI or dynamic contrast-enhanced MRI (DCE-MRI) with MR spectroscopic imaging (MRSI) is improving the evaluation of cancer location, size, and extent, while providing an indication of tumor aggressiveness. Pretreatment knowledge of these prognostic variables is essential for achieving minimally invasive, patient-specific therapy.

引用

页码：107 / 120

页数：14

共 80 条

[1]

*AM CANC SOC, 2007, PUBLICATION AM CANC

[2]

Amis E S Jr, 2000, Radiology, V215 Suppl, P703

[3] Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].

Bander, NH ;

Nanus, DM ;

Milowsky, MI ;

Kostakoglu, L ;

Vallabahajosula, S ;

Goldsmith, SJ .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677

[4] Variations in morbidity after radical prostatectomy. [J].

Begg, CB ;

Riedel, ER ;

Bach, PB ;

Kattan, MW ;

Schrag, D ;

Warren, JL ;

Scardino, PT .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1138-1144

[5] Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience [J].

Bellin, MF ;

Roy, C ;

Kinkel, K ;

Thoumas, D ;

Zaim, S ;

Vanel, D ;

Tuchmann, C ;

Richard, F ;

Jacqmin, D ;

Delcourt, A ;

Challier, E ;

Lebret, T ;

Cluzel, P .

RADIOLOGY, 1998, 207 (03) :799-808

[6] Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging [J].

Beyersdorff, D ;

Taupitz, M ;

Winkelmann, B ;

Fischer, T ;

Lenk, S ;

Loening, SA ;

Hamm, B .

RADIOLOGY, 2002, 224 (03) :701-706

[7] NMR CHEMICAL-SHIFT IMAGING IN 3 DIMENSIONS [J].

BROWN, TR ;

KINCAID, BM ;

UGURBIL, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (11) :3523-3526

[8] A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer [J].

Cagiannos, I ;

Karakiewicz, P ;

Eastham, JA ;

Ohori, M ;

Rabbani, F ;

Gerigk, C ;

Reuter, V ;

Graefen, M ;

Hammerer, PG ;

Erbersdobler, A ;

Huland, H ;

Kupelian, P ;

Klein, E ;

Quinn, DI ;

Henshall, SM ;

Grygiel, JJ ;

Sutherland, RL ;

Stricker, PD ;

Morash, CG ;

Scardino, PT ;

Kattan, MW .

JOURNAL OF UROLOGY, 2003, 170 (05) :1798-1803

[9] Prostate-specific antigen best practice policy - part II: Prostate cancer staging and post-treatment follow-up [J].

Carroll, P ;

Coley, C ;

McLeod, D ;

Schellhammer, P ;

Sweat, G ;

Wasson, J ;

Zietman, A ;

Thompson, I .

UROLOGY, 2001, 57 (02) :225-229

[10] High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence [J].

Chen, Albert P. ;

Cunningham, Charles H. ;

Kurhanewicz, John ;

Xu, Duan ;

Hurd, Ralph E. ;

Pauly, John M. ;

Carvajal, Lucas ;

Karpodinis, Kostas ;

Vigneron, Daniel B. .

MAGNETIC RESONANCE IMAGING, 2006, 24 (07) :825-832

← 1 2 3 4 5 6 7 8 →